InMed Pharmaceuticals (INM) Shares Outstanding (Weighted Average) (2019 - 2026)

InMed Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 8 years, with the latest figure at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 395.74% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 395.74% YoY), and the FY2025 full-year result was $975985.0, up 156.13% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $4.0 million, up from $4.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $13.3 million in Q1 2022, with the low at $166410.0 in Q3 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $2.5 million across 5 years, with a median of $803909.0 in 2025.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) plunged 84.44% — and 2025, when it soared 537.7%.
• InMed Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $13.3 million in 2022, then slumped by 97.88% to $282541.0 in 2023, then jumped by 150.07% to $706546.0 in 2024, then surged by 459.7% to $4.0 million in 2025, then advanced by 0.78% to $4.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $4.0 million (Q1 2026), $4.0 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.